Regen BioPharma Files Patent Application on Personalized Checkpoint Inhibitor Cancer Immunotherapy

Company Intends to Utilize NR2F6 Gene-Silenced Immune Cells to Amplify Body's Own Anti-Tumor Defenses

Nov 04, 2015, 08:30 ET from Regen BioPharma Inc.

SAN DIEGO, November 4, 2015 /PRNewswire/ --

Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced the filing of a patent application covering gene silencing of NR2F6 (a Protein Coding Gene) in various immune cell populations as a means of selectively activating the immune system to kill cancer cells.  Researchers at Regen BioPharma have previously demonstrated that NR2F6 is an inhibitor of T cell development and activation[1]. In addition, a recent independent publication showed that immune cells from mice lacking NR2F6 are capable of killing prostate cancer cells[2]. The current patent application integrates the Company's knowledge of NR2F6 function, with clinically-applicable gene silencing techniques to create a patient-specific immune based therapy.  

Regen BioPharma has extensive experience in developing cell based therapeutics in a rapid and inexpensive manner. The current patent filing represents a therapeutic approach that involves manipulation of the patient's own cells outside of the body.  Given that in the current approach gene silencing is performed on isolated cells outside of the body and not systemically throughout the whole body, the Company anticipates the current approach will possess lower regulatory hurdles as compared to standard gene silencing therapies.

The current patent application adds to the existing Regen BioPharma intellectual property position in the NR2F6 space including US patent # 9,091,696 covering means of screening for inhibitors of NR2F6, as well as published patent applications # 14/595078 covering means of modulating hematopoietic stem cell differentiation, # 14/571262 covering methods of killing cancer cells, #14/572574 covering means of treating myelodysplastic syndrome, and # 13/652395 and # 12/619290 covering compositions of matter and means of modulating biological systems by NR2F6 manipulation.

"At Regen BioPharma our main goal is development of clinically applicable therapeutic approaches that can be brought to patients as soon as possible.  The new patent application filed represents an easy to translate approach, which we believe will lead to a new class of checkpoint inhibitors for treatment of cancer patients," said David Koos, Chairman and CEO of Regen BioPharma.

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.


1. Ichim et al. Exp Hematol. 2014 Jan;42(1):46-58

2. Hermann-Kleiter et al. Cell Rep. 2015 Sep 29;12(12):2072-85.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


Regen BioPharma Inc. 
David R. Koos, PhD 
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax

SOURCE Regen BioPharma Inc.